Unione Europea - italiano - EMA (European Medicines Agency)

valneva austria gmbh - covid-19 vaccine (inactivated, adjuvanted, adsorbed) - covid-19 virus infection - vaccini - covid-19 vaccine (inactivated, adjuvanted) valneva is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 to 50 years of age.  the use of this vaccine should be in accordance with official recommendations.

Unione Europea - italiano - EMA (European Medicines Agency)

moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaccini - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older.  spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.

Unione Europea - italiano - EMA (European Medicines Agency)

janssen-cilag international nv - adenovirus type 26 encoding the sars-cov-2 spike glycoprotein (ad26.cov2-s) - covid-19 virus infection - vaccini - jcovden is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 years of age and older. l'uso di questo vaccino dovrebbe essere in conformità con le raccomandazioni ufficiali.

Unione Europea - italiano - EMA (European Medicines Agency)

astrazeneca ab - chadox1-sars-cov-2 - covid-19 virus infection - vaccini - vaxzevria is indicated for active immunisation to prevent covid 19 caused by sars cov 2, in individuals 18 years of age and older. l'uso di questo vaccino dovrebbe essere in conformità con le raccomandazioni ufficiali.

Italia - italiano - Ministero della Salute

siapa s.r.l. - metidation; - concentrato emulsionabile - 19.0 g i valori indicati sono per 100 g di prodotto. - insetticida

Italia - italiano - Ministero della Salute

diachem s.p.a. - metidation; - concentrato emulsionabile - 19.0 g i valori indicati sono per 100 g di prodotto. - insetticida

Italia - italiano - Ministero della Salute

istituto zooprofilattico sperimentale lombardia - emilia-romagna - brucelle ceppo 19 vive in fase s - brucelle ceppo 19 vive in fase s - 60 miliardi

Italia - italiano - Ministero della Salute

bayer ag - thiencarbazone; isoxaflutole; cyprosulfamide; - sospensione concentrata - 7.6 %; 19.1 %; 12.7 % i valori indicati sono per 100 g di prodotto. - isoxaflutole; 19,1%; (225; g/l); thiencarbazone-methyl; 7,6%; (90; g/l); cyprosulfamide; (antidoto; agronomico); 12,7%; (150; g/l) - diserbante

Unione Europea - italiano - EMA (European Medicines Agency)

novavax cz, a.s. - sars cov-2 (original) recombinant spike protein, sars-cov-2 (omicron xbb.1.5) recombinant spike protein - covid-19 virus infection - covid-19 vaccines - nuvaxovid is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. l'uso di questo vaccino dovrebbe essere in conformità con le raccomandazioni ufficiali. nuvaxovid xbb. 5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. l'uso di questo vaccino dovrebbe essere in conformità con le raccomandazioni ufficiali.

Italia - italiano - Ministero della Salute

gruppo industriale di giacomo s.r.l. - kit chirurgici (sono compresi solo i kit certificati ce come tali)